Abstract
In the last years, guidelines for the treatment of hypertension recommended individualized blood pressure goals for geriatric population because of elderly susceptibility to adverse outcomes and higher mortality rate deriving from the excessive blood pressure lowering, especially in “frail” elderly. Recent findings from the SPRINT study, which demonstrated that intensive blood pressure lowering was associated with lower rates of cardiovascular events and mortality in both hypertensive fit and frail elderly subjects compared to standard treatment, heavily influenced the recent US guidelines. In SPRINT sub-study analysis of adults aged ≥75 years, the most controversial issue appears the method of blood pressure measurement, the selection of patients and related-frailty degree that appears to be very light. Accordingly, it has been described that light frailty is related to good outcomes in older adults. SPRINT findings in “frail elderly patients” cannot be applied to the clinical practice because this condition has been clearly under-estimated. Thus, frailty status should be routinely and correctly quantified in order to identify the frailty degree and to find the best harms–benefits balance of antihypertensive drug treatment in frail older adults.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bavishi C, Goel S, Messerli FH. Isolated systolic hypertension: an update after SPRINT. Am J Med. 2016;129:1251–8.
Hulley SB, Furberg CD, Gurland B, McDonald R, Perry HM, Schnaper HW, et al. Systolic hypertension in the elderly program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol. 1985;56:913–20.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet Lond Engl. 1997;350:757–64.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.
SPRINT Research Group, Wright, Williamson JT, Whelton JD, Snyder PK, Sink JK. KM, et al. A randomized trial of intensive versus standard blood-pressure. Control N Engl J Med. 2015;373:2103–16.
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA . 2016;315:2673–82.
JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res J Jpn Soc Hypertens. 2008;31:2115–27.
Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertens Dallas 1979. 2010;56:196–202.
Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE Study. JAMA Intern Med. 2015;175:989–95.
Koh AS, Talaei M, Pan A, Wang R, Yuan J-M, Koh W-P. Systolic blood pressure and cardiovascular mortality in middle-aged and elderly adults-the Singapore Chinese health study. Int J Cardiol. 2016;219:404–9.
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2013;31:1281–357.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA . 2014;311:507–20.
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertens Greenwich Conn. 2014;16:14–26.
Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American heart association, American college of cardiology, and American society of hypertension. Circulation. 2015;131:e435–70. CIR.0000000000000207
Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004;15:348–57.
Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertens Dallas 1979. 2016;67:808–12.
Kjeldsen SE, Narkiewicz K, Hedner T, Mancia G. The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Press. 2016;25:63–6.
Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015;66:848–60.
Cushman WC, Whelton PK, Fine LJ, Wright JT, Reboussin DM, Johnson KC, et al. SPRINT trial results: latest news in hypertension management. Hypertens Dallas 1979. 2016;67:263–5.
Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American college of physicians and the American academy of family physicians. Ann Intern Med. 2017;166:430–7.
Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–76.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2017. http://linkinghub.elsevier.com/retrieve/pii/S0735109717415191 Accessed 23 Jan 2018.
Strandberg TE, Pitkälä KH. Frailty in elderly people. Lancet Lond Engl. 2007;369:1328–9.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–156.
Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722–7.
Muller M, Smulders YM, Leeuw PW, de, Stehouwer CDA. Treatment of hypertension in the oldest old: a critical role for frailty? Hypertension . 2014;63:433–41.
Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) Study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.
Weiss J, Freeman M, Low A, Fu R, Kerfoot A, Paynter R, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis. Ann Intern Med. 2017;166:419–29.
Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C. Treating hypertension in the very elderly—benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J. 2014;35:1712–8.
Ogliari G, Westendorp RGJ, Muller M, Mari D, Torresani E, Felicetta I, et al. Blood pressure and 10-year mortality risk in the Milan Geriatrics 75+Cohort Study: role of functional and cognitive status. Age Ageing. 2015;44:932–7.
Mossello E, Pieraccioli M, Nesti N, Bulgaresi M, Lorenzi C, Caleri V, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med. 2015;175:578–85.
Pajewski NM, Williamson JD, Applegate WB, Berlowitz DR, Bolin LP, Chertow GM, et al. Characterizing frailty status in the systolic blood pressure intervention trial. J Gerontol A Biol Sci Med Sci. 2016;71:649–55.
Abete P, Basile C, Bulli G, Curcio F, Liguori I, Della-Morte D, et al. The Italian version of the “frailty index” based on deficits in health: a validation study. Aging Clin Exp Res. 2017;29:913–26.
Liguori I, Aran L, Bulli G, Russo G, Curcio F, Sasso G, et al. Statins in cardiovascular prevention in the oldest-old. A black hole. Off J Ital Soc Gerontol Geriatr. 2017;65:263–270.
Vischer UM, Safar ME, Safar H, Iaria P, Le Dudal K, Henry O, et al. Cardiometabolic determinants of mortality in a geriatric population: is there a “reverse metabolic syndrome”? Diabetes Metab. 2009;35:108–14.
Acknowledgements
All authors contributed to the writing and editing of the manuscript and approved the final version submitted for publication. The manuscript has not been published or submitted elsewhere. No source of funds. No additional funding was obtained for this review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Russo, G., Liguori, I., Aran, L. et al. Impact of SPRINT results on hypertension guidelines: implications for “frail” elderly patients. J Hum Hypertens 32, 633–638 (2018). https://doi.org/10.1038/s41371-018-0086-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-018-0086-6
This article is cited by
-
A clinical algorithm to determine target blood pressure in the elderly: evidence and limitations from a clinical perspective
Clinical Hypertension (2022)
-
Management of Hypertension in the Elderly and Frail Patient
Drugs & Aging (2022)
-
The degree of frailty as a translational measure of health in aging
Nature Aging (2021)
-
Intensive blood pressure lowering: a practical review
Clinical Hypertension (2020)
-
Frailty and hypertension in older adults: current understanding and future perspectives
Hypertension Research (2020)